Journal
KIDNEY INTERNATIONAL
Volume 79, Issue -, Pages S20-S27Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2010.512
Keywords
diabetes mellitus; type 2; glucosuria; SGLT2 inhibitors; sodium-glucose transport proteins
Categories
Funding
- AstraZeneca
- Bristol-Myers Squibb
Ask authors/readers for more resources
Glucose is freely filtered in the glomeruli before being almost entirely reabsorbed into circulation from the proximal renal tubules. The sodium-glucose cotransporter 2 (SGLT2), present in the Si segment of the proximal tubule, is responsible for the majority of glucose reabsorption. SGLT2 inhibitors reduce glucose reabsorption and increase urinary glucose excretion. In animal models and humans with type 2 diabetes, this effect is associated with reduced fasting and postprandial blood glucose levels, and reduced hemoglobin A1c. Animal studies suggest that reduction of hyperglycemia with SGLT2 inhibitors may also improve insulin sensitivity and preserve beta-cell function. Urinary excretion of excess calories with SGLT2 inhibitors is also associated with reduction in body weight. Modest reductions in blood pressure have been noted with SGLT2 inhibitors, consistent with a mild diuretic action. Some C-glucoside SGLT2 inhibitors, such as dapagliflozin, have pharmacokinetic properties that make them amenable to once-daily dosing. Kidney International (2011) 79 (Suppl 120), S20-S27; doi:10.1038/ki.2010.512
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available